NovAliX Partners with Kyowa Hakko Kirin
News Jan 17, 2013
Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets. NovAliX will generate novel lead candidates using the broad spectrum of its biophysical capabilities and its medicinal chemistry expertise.
Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.
Stephan Jenn, President of NovAliX, stated, "For NovAliX this drug discovery alliance represents a significant development of our established relation with Kyowa Hakko Kirin. This drug discovery collaboration with a leading Japanese pharmaceutical company also confirms the quality of our discovery platforms and its ability to deliver valuable lead candidates."
Marine Microbes may be Responsible for Production of the Greenhouse GasNews
Industrial and agricultural activities produce large amounts of methane, a greenhouse gas that contributes to global warming. Many bacteria also produce methane as a byproduct of their metabolism. Some of this naturally released methane comes from the ocean, a phenomenon that has long puzzled scientists because there were no known methane-producing organisms living near the ocean’s surface but new evidence is helping to solve the mystery.READ MORE
New Research into an Old Antibiotic Could Lead to More Effective TB DrugsNews
Tuberculosis, and other life-threatening microbial diseases, could be more effectively tackled with future drugs, thanks to new research into an old antibiotic by the University of Warwick and The Francis Crick Institute.READ MORE
Computer Simulations Reveal Roots of Drug ResistanceNews
New supercomputer simulations together with crystallography and cryo-EM, have revealed the role of transport proteins called efflux pumps in creating drug-resistance in bacteria. This research could lead to improving the effectiveness of drugs against life-threatening diseases and restoring the efficacy of defunct antibiotics.READ MORE